JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Plasma proteometabolome in lung cancer: exploring biomarkers through bidirectional Mendelian randomization and colocalization analysis

  • 0Department of Thoracic Surgery and Institute of Thoracic Oncology, National Clinical Research Centre for Geriatrics, West China Hospital, Sichuan University, Chengdu 610041, China.
Human Molecular Genetics +

|

July 16, 2024

|

July 16, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

This study identifies novel plasma protein and metabolite biomarkers for lung cancer detection. These non-invasive markers could improve early diagnosis and management for at-risk individuals.

Area Of Science

  • Genetics
  • Oncology
  • Biomarker Discovery

Background

  • Lung cancer screening involves invasive biopsies with significant complications.
  • Non-invasive diagnostic biomarkers are crucial for improving lung cancer management in at-risk populations.

Purpose Of The Study

  • To investigate plasma proteome and metabolome for novel lung cancer biomarkers using Mendelian Randomization (MR).
  • To identify potential non-invasive diagnostic and etiological insights for lung cancer subtypes.

Main Methods

  • Employed bidirectional Mendelian Randomization (MR) and co-localization analyses.
  • Investigated associations between plasma proteins (SFTPB, KDELC2, TCL1A, CNTN1) and metabolites (theobromine, paraxanthine, caffeine, arachidonate) with lung cancer subtypes.
  • Utilized single-cell sequencing data of normal lung tissue to explore SFTPB's role.

Main Results

  • Identified inverse associations of SFTPB and KDELC2 with lung adenocarcinoma (LUAD).
  • Found positive associations of TCL1A with lung squamous cell carcinoma (LUSC) and CNTN1 with small cell lung cancer (SCLC).
  • Revealed significant correlations of specific metabolites and their ratios with LUAD and LUSC, including negative correlations for theobromine and paraxanthine.

Conclusions

  • Novel plasma protein and metabolite biomarkers for lung cancer (LUAD, LUSC, SCLC) have been identified.
  • Findings suggest potential for developing non-invasive diagnostic tools and offer insights into lung cancer etiology.
  • The study highlights SFTPB's potential role in lung carcinogenesis.

Keywords: